CA3024584A1 - Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules - Google Patents

Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules Download PDF

Info

Publication number
CA3024584A1
CA3024584A1 CA3024584A CA3024584A CA3024584A1 CA 3024584 A1 CA3024584 A1 CA 3024584A1 CA 3024584 A CA3024584 A CA 3024584A CA 3024584 A CA3024584 A CA 3024584A CA 3024584 A1 CA3024584 A1 CA 3024584A1
Authority
CA
Canada
Prior art keywords
soft gel
capsule
gel capsule
liquid formulation
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3024584A
Other languages
English (en)
French (fr)
Inventor
Martin Purpura
Ralf Jaeger
Jie Gu
Xiong ZHENG
Yaohua Zhang
Lingwei DAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsi Group Co Ltd
Original Assignee
Dai Lingwei
Zheng Xiong
TSI Group Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dai Lingwei, Zheng Xiong, TSI Group Ltd USA filed Critical Dai Lingwei
Publication of CA3024584A1 publication Critical patent/CA3024584A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3024584A 2016-05-25 2017-05-25 Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules Pending CA3024584A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341464P 2016-05-25 2016-05-25
US62/341,464 2016-05-25
PCT/US2017/034551 WO2017205673A1 (en) 2016-05-25 2017-05-25 Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules

Publications (1)

Publication Number Publication Date
CA3024584A1 true CA3024584A1 (en) 2017-11-30

Family

ID=60411620

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3024584A Pending CA3024584A1 (en) 2016-05-25 2017-05-25 Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules

Country Status (12)

Country Link
US (3) US10959957B2 (enExample)
EP (1) EP3463327B1 (enExample)
JP (1) JP6929939B2 (enExample)
KR (1) KR102384266B1 (enExample)
CN (2) CN121177244A (enExample)
AU (1) AU2017270219B2 (enExample)
CA (1) CA3024584A1 (enExample)
CO (1) CO2018014085A2 (enExample)
MX (1) MX2018014407A (enExample)
MY (1) MY199597A (enExample)
RU (1) RU2018145520A (enExample)
WO (1) WO2017205673A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111888325A (zh) * 2020-08-04 2020-11-06 瑞希(重庆)生物科技有限公司 一种卡拉胶凝胶、药物赋形剂和皮肤外用制剂
JP7750505B2 (ja) * 2021-10-14 2025-10-07 中日本カプセル 株式会社 カプセル及びカプセルの製造方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870062A (en) * 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
US5200191A (en) 1991-09-11 1993-04-06 Banner Gelatin Products Corp. Softgel manufacturing process
US5569466A (en) 1995-05-17 1996-10-29 R. P. Scherer Corporation Fill compositions for soft elastic gel capsules
US6340473B1 (en) * 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
DE10064312C2 (de) 2000-12-22 2003-05-22 Degussa Cholinpyruvat-Hydrat, Verfahren zu dessen Herstellung, Cholinpyruvat-Hydrat enthaltende Formulierung sowie deren Verwendung
US7740878B2 (en) * 2001-10-22 2010-06-22 Danisco A/S Use of betaine to enhance exercise performance
ES2294197T3 (es) 2001-12-21 2008-04-01 Supernus Pharmaceuticals, Inc. Formulacion de capsula oral con estabilidad fisica aumentada.
DE10208568A1 (de) 2002-02-27 2003-09-18 Degussa Bioactives Deutschland Verbindung, enthaltend Kreatin, eine Säure-Komponente und/oder einen Komplex-Bildner
DE10217557A1 (de) 2002-04-19 2003-11-06 Degussa Bioactives Gmbh Funktionsnahrungsmittel enthaltend eine Phospholipid-haltige stabile Matrix
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US8231896B2 (en) * 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
DE102004060914A1 (de) 2004-12-17 2006-07-06 Bioghurt Biogarde Gmbh & Co. Kg Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen
EP2242489A1 (en) * 2005-02-15 2010-10-27 Jallal Messadek Combination therapeutic compositions and method of use
DE102005061765A1 (de) 2005-05-19 2006-11-23 Degussa FreshTech Beverages LLC, Milwaukee Füllmaterial für einen Getränkebehälter
CN101574146B (zh) * 2008-05-07 2012-06-13 北京康比特体育科技股份有限公司 一种含有hmb的运动营养补剂
JP2009153529A (ja) 2009-04-17 2009-07-16 Tsujido Chemical Corp 食品組成物
ES2608483T3 (es) * 2009-12-18 2017-04-11 Metabolic Technologies, Inc. Método mejorado de administración de beta-hidroxi-beta-metilbutirato (HMB)
MX2013007347A (es) 2010-12-22 2013-08-01 Abbott Lab Productos nutricionales que comprenden beta-hidroxi-beta metilbutirato de calcio y acido linoleico conjugado.
RU2631597C2 (ru) * 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
EP3733171B1 (en) * 2012-09-10 2023-10-25 Metabolic Technologies, LLC Compositions comprising hmb and atp as well as their use
AU2013344753B2 (en) 2012-11-13 2018-09-27 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
US20140272000A1 (en) 2013-03-14 2014-09-18 Metabolic Technologies, Inc. Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same
WO2014152098A1 (en) * 2013-03-15 2014-09-25 Banner Pharmacaps Inc. Non-gelatin enteric soft capsules
JP2016520050A (ja) 2013-05-01 2016-07-11 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 老化筋肉再生の増強方法
EP3082778B1 (en) * 2013-12-18 2019-04-03 Capsugel Belgium NV Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid
US20150366813A1 (en) * 2014-06-20 2015-12-24 Banner Life Sciences Llc Liquid-filled immediate release soft gelatin capsules
JP2018090504A (ja) * 2016-11-30 2018-06-14 株式会社東洋新薬 筋肉増強用組成物

Also Published As

Publication number Publication date
EP3463327A4 (en) 2020-01-22
US20250057773A1 (en) 2025-02-20
KR20190021259A (ko) 2019-03-05
RU2018145520A3 (enExample) 2020-08-26
MX2018014407A (es) 2019-02-21
EP3463327A1 (en) 2019-04-10
EP3463327C0 (en) 2024-04-17
RU2018145520A (ru) 2020-06-25
US12133920B2 (en) 2024-11-05
KR102384266B1 (ko) 2022-04-06
AU2017270219B2 (en) 2023-03-16
WO2017205673A1 (en) 2017-11-30
JP2019517576A (ja) 2019-06-24
CN121177244A (zh) 2025-12-23
CO2018014085A2 (es) 2019-03-18
US10959957B2 (en) 2021-03-30
JP6929939B2 (ja) 2021-09-01
US20170340572A1 (en) 2017-11-30
BR112018073949A2 (pt) 2019-02-26
US20210212953A1 (en) 2021-07-15
AU2017270219A1 (en) 2018-11-29
MY199597A (en) 2023-11-08
BR112018073949A8 (pt) 2023-03-21
EP3463327B1 (en) 2024-04-17
CN109562087A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
US20250057773A1 (en) Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
EP1062274B1 (en) Polyvinyl alcohol compositions
EP3082778B1 (en) Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid
JP7347474B2 (ja) 経口フィルム製剤
EP3796896B1 (en) PHARMACEUTICAL COMPOSITION OF ADRENALINE
CN107530358A (zh) 含有甾醇和增溶剂的凝胶胶囊
KR20120062208A (ko) 홍삼 오일을 부형제 오일로 함유하는 연질캡슐제
CN1287794C (zh) 用于软胶囊的含有长春瑞滨的口服医药组合物及治疗方法
HK40005738A (en) Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
EP2830607A1 (en) Polyvinylpyrrolidone-containing acetaminophen liquid formulations
BR112018073949B1 (pt) Cápsula gelatinosa mole de ácido hidroxil-3-metilbutírico, e, método para formar uma cápsulagelatinosa mole de ácido hidroxil-3-metilbutírico
CN106540265A (zh) 一种奥格列汀药物组合物及其制备方法
JP2018065775A (ja) ナルフラフィン塩酸塩を含有するカプセル充填用組成物、軟カプセル剤及びその製造方法
JP2009046436A (ja) コーティング方法及び処理物
CN105395512A (zh) 一种盐酸环苯扎林控释片
KR101236528B1 (ko) 덱시부프로펜 액상 조성물을 함유하는 밀봉된 경질캡슐제
CN104434861A (zh) 盐酸氨溴索渗透泵控释片及其制备方法
BRPI0519466B1 (pt) dispersão sólida estável de um derivado de alcalóide de vinca e processo para a fabricação do mesmo
KR101346750B1 (ko) 나프록센 액상 조성물을 함유하는 밀봉된 경질캡슐제
JP2023041452A (ja) 軟カプセル剤及びその製造方法、並びに軟カプセル剤の吸湿を抑制する方法
EA041152B1 (ru) Пероральное лекарственное средство для щитовидной железы

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525